Will Knox is the Chief Executive Officer and Executive Director of Tetratherix Limited, an Australian biomedical technology company specializing in regenerative medicine and biomaterial innovation. Knox joined Tetratherix as CEO in 2021 after working with the leadership team since 2019 as a director and advisor. His career spans more than 20 years in the medical and biological technology development field, including roles in multinational corporations, early-stage companies, and investment projects.​​

He is recognized for his expertise in leading development and commercialization of medical technologies and healthcare innovations and has founded several Australian life sciences companies, with successful exits such as the acquisition of uHealth by Device Technologies in 2017. Knox holds an undergraduate degree from the University of Technology Sydney. At Tetratherix, he oversees the transformation of the company from research and development into a commercial-stage biomedical business, notably leading a successful A$25 million IPO in 2025 to fund new manufacturing capabilities and global product launches.​​

Tetratherix’s innovative Tetramatrix™ platform is used in various clinical areas such as bone regeneration, tissue spacing, and scar prevention, and is expected to see FDA approval with initial launches in the US in 2026. Knox is widely respected for his leadership, entrepreneurial approach, and commitment to advancing clinical and commercial biomedical outcomes on a global scale.